Core Viewpoint - Arvinas, Inc. is advancing its investigational drug ARV-393, a PROTAC designed to degrade the BCL6 protein, which is a significant driver of B-cell lymphomas, and will present preclinical data in December 2025 at the ASH Annual Meeting [1][3]. Group 1: About ARV-393 - ARV-393 targets the BCL6 protein, which plays a crucial role in B-cell lymphoma by repressing cell cycle checkpoints and apoptosis, making it a challenging target for traditional therapies [3]. - The drug is currently in a Phase 1 clinical trial for patients with non-Hodgkin lymphoma, indicating its potential therapeutic application in this area [3]. Group 2: About Arvinas - Arvinas is a clinical-stage biotechnology company focused on developing therapies that utilize its PROTAC platform to selectively degrade disease-causing proteins [4]. - The company is also developing other investigational drugs, including ARV-102 for neurodegenerative disorders, ARV-806 for mutated cancers, and vepdegestrant for ER+/HER2-breast cancer [4].

Core Insights - MediWound Ltd. has successfully completed the commissioning of its expanded GMP manufacturing facility in Yavne, Israel, which is a significant step towards increasing production capacity for NexoBrid® by approximately sixfold by the end of 2025 [1][2] Company Overview - MediWound Ltd. is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair, with its FDA-approved product NexoBrid® indicated for the enzymatic removal of eschar in thermal burns [4] - NexoBrid® is approved for use in over 40 countries, including the United States, European Union, and Japan, and is designed to selectively remove non-viable tissue while preserving viable tissue [3] Manufacturing and Supply Capacity - The newly expanded facility will enable a scalable and reliable global supply of NexoBrid across more than 40 approved markets, contingent upon the completion of regulatory reviews [2] - The operational readiness of the expanded facility is expected by year-end 2025, which will help meet the growing global demand for NexoBrid [2][4]

Core Viewpoint - MoonLake Immunotherapeutics faces a securities class action lawsuit following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a significant drop in share price by approximately 90% [1][2][6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases, specifically targeting cytokines IL-17A and IL-17F [3][4]. Legal Proceedings - A class action lawsuit has been filed against MoonLake, alleging that the company misled investors regarding the trial design and efficacy data of SLK prior to the announcement of the trial results [1][2][3]. - The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline set for December 15, 2025 [3]. Trial Results and Market Reaction - The Phase 3 trial results revealed that only one of the two trials achieved statistical significance, with the efficacy being substantially lower than that of a competitor's product, BIMZELX [6]. - Following the announcement, MoonLake's share price plummeted by $55.75, representing a 90% decrease, which analysts described as a "worst case outcome" [2][6]. Product Comparison - SLK's commercial prospects were heavily reliant on demonstrating efficacy comparable to or superior to BIMZELX, which is already FDA-approved for the same indication [4]. - The lawsuit claims that MoonLake made false statements regarding the advantages of SLK's Nanobody structure over traditional monoclonal antibodies, asserting that it would lead to superior clinical benefits [5]. Investor Communication - Throughout the class period, MoonLake promoted SLK's structural advantages, claiming it could achieve benefits unattainable by monoclonal antibodies and positioned it as a potential "gold standard" treatment [5]. - The lawsuit alleges that these statements were misleading and that the company failed to disclose critical information about SLK's clinical efficacy [5][6].

Core Points - Mydecine Innovations Group Inc. has successfully closed debt settlement agreements totaling USD $1,386,391 and CAD $9,432,107 to settle outstanding debts with various creditors [1][2] - The company issued five convertible debentures to creditors as part of the debt settlements to preserve cash for working capital and improve its financial situation [2] Debt Settlement Agreements - The company entered into debt forgiveness agreements to settle USD $1,386,391 owed to two former insiders, issuing convertible debentures with an aggregate principal amount of USD $100,000 [4] - A debt settlement agreement with CEO Josh Bartch was made to settle CAD $1,309,836 of unpaid management fees, with a convertible debenture issued for the same amount [5] - A settlement with Pioneer Garage Limited was made for CAD $7,878,792, with a convertible debenture issued under similar terms as the Bartch agreement [6] - An additional settlement with an arm's length creditor for CAD $243,479 was fully settled through a secured convertible debenture of USD $100,000, which bears interest at 1% per month [9] Share Consolidation - The company announced a share consolidation effective October 21, 2025, converting every fifty old common shares into one new common share, reducing the outstanding shares from 61,755,385 to approximately 1,235,107 [12][13] - The share consolidation aims to enhance the company's attractiveness for financing opportunities and facilitate the restructuring of existing liabilities [15]

Core Insights - Sharp Therapeutics Corp. is set to present preclinical data for its lead program '901, aimed at treating Gaucher disease and GBA Parkinson's disease, at the World Orphan Drug Congress 2025 in Amsterdam from October 27 to 29, 2025 [1][2] Company Overview - Sharp Therapeutics is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics for genetic diseases, with a discovery platform that produces compounds to restore activity in mutated proteins [4] Clinical Pipeline - The company’s pipeline includes programs targeting Gaucher disease, Niemann-Pick disease type C, and familial frontotemporal dementia, with '901 being the most advanced candidate designed to address lysosomal storage disorders caused by GBA enzyme deficiencies [2][3] Leadership Statement - The CEO of Sharp Therapeutics expressed the company's commitment to developing pill-based medicines that restore function in defective proteins, aiming to improve the lives of patients with genetic diseases [3]

Group 1 - The biotechnology company has launched a new direct-to-patient program called AmgenNow, which initially focuses on its drug Repatha [1]

Core Viewpoint - SciSparc Ltd. has mutually terminated its planned merger with AutoMax Motors Ltd., concluding a deal aimed at expanding into Israel's automotive market [1][2]. Loan Repayment Terms - AutoMax is required to repay $4.25 million with 9% annual interest by January 1, 2028, and a separate $2 million loan will be repaid in monthly installments of $60,000 starting November 20, 2025, with an 8% annual interest rate [2]. Background on the Merger - The merger was initially agreed upon in April 2024, with plans for SciSparc to acquire AutoMax through a reverse merger structure. The deal received approval from both companies' shareholders in 2025 [2]. Strategic Focus After Termination - Following the cancellation of the merger, SciSparc will continue to concentrate on its pipeline of treatments for central nervous system disorders and advance drug discovery using quantum algorithms [3]. Price Action - SciSparc shares experienced a premarket increase of 2.32%, trading at $4.86 [4].

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, leading to a significant drop in stock price [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2]. Trial Results - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were disappointing and raised concerns about the drug's regulatory approval and commercial viability [3]. - The stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025, following the announcement of the trial results [3]. Legal Implications - Investors in MoonLake are encouraged to seek legal options due to the potential violations of securities laws related to the trial results [1][4]. Law Firm Background - Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and shareholder litigation, with a strong track record of recovering significant amounts for clients [6].

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Sirius Therapeutics 靖因藥業 * (Incorporated in the Cayman Islands with limited liability) WARNING The publication of t ...

Core Insights - MediWound has received marketing authorization for NexoBrid from Australia's Therapeutic Goods Administration (TGA), allowing its use for both adults and children with deep partial- and full-thickness thermal burns [1][2] - NexoBrid is now authorized in 45 countries, establishing it as a new standard of care in burn management, with a commercial launch expected in Australia in Q4 2025 [2][3] - The company is expanding its manufacturing capabilities, which are on track for completion by the end of 2025, to meet global demand for NexoBrid [2][3] Product Overview - NexoBrid is a topically administered biological orphan drug designed for the enzymatic removal of eschar in patients with deep partial- and full-thickness thermal burns, preserving viable tissue while removing non-viable tissue [4] - The product is already approved in over 40 countries, including the United States, European Union, and Japan [4][5] Company Background - MediWound Ltd. is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair, with NexoBrid being its FDA-approved product [5] - The company is also advancing EscharEx, a late-stage investigational therapy for chronic wound debridement, which has shown clinical advantages over leading products in the market [5] Market Expansion - The TGA approval of NexoBrid is seen as a significant step in improving access to innovative burn care solutions in Australia and opens opportunities for expansion into the broader Asia-Pacific region [3] - Balance Medical, MediWound's exclusive partner in Australia, is expected to initiate the commercial launch of NexoBrid in the fourth quarter of 2025 [2][3]